Table 1.

Entrectinib clinical trials

Study	Patient population	Study design	Dose and schedule
ALKA-372-0012	Locally advanced or metastatic cancer targeting NTRK1, NTRK2, NTRK3, ROS1, or ALK molecular alterations	Phase I basket	100–1,800 mg/m2
			Schedule A (n=19): fasted, 4 days on and 3 days off for 21 of 28 days
			Schedule B (n=29): fed, continuous daily dosing for 28 days
			Schedule C (n=6): fed, 4 days on and 3 days off for 28 days
STARTRK-12	Locally advanced or metastatic cancer targeting NTRK1/2/3, ROS1, or ALK molecular alterations	Phase I basket	100–1,800 mg/m2
			Fed, continuous daily dosing for 28 days (n=65)
STARTRK-236	Solid tumors that harbor an NTRK1/2/3, ROS1, or ALK gene fusion	Phase II basket	600 mg
			Fed, continuous daily dosing for 28 days
STARTRK-NG26	Children with recurrent or refractory solid tumors and primary CNS tumors, with or without TRK1/2/3, ROS1, or ALK fusions	Phase I/Ib	250 mg/m2
			Fed, continuous daily dosing for 28 days

Abbreviations: ALK, anaplastic lymphoma kinase; NTRK, neurotrophic tyrosine kinase; ROS1, ROS proto-oncogene 1; CNS, central nervous system.